Product news

Share this article:
The FDA has approved Eli Lilly's Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder. The approval makes Cymbalta the first serotonin-norepinephrine reuptake inhibitor approved for reducing pain in patients with fibromyalgia. 

Allergan said the FDA has approved Trivaris (triamcinolone acetonide injectable suspension), a synthetic glucocorticoid corticosteroid with anti-inflammatory action to treat sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.